on Marinomed Biotech AG
Marinomed Biotech AG Explores Strategic Alternatives for Marinosolv Platform
On October 6, 2025, Marinomed Biotech AG announced its decision to explore strategic options for its Marinosolv platform. This follows the recent success of capital measures and has been approved by the Supervisory Board. Marinomed is considering strategic partnerships for its Budesolv and Tacrosolv projects, with additional input from a strategist. To aid this process, the company is collaborating with a consulting firm.
Marinomed, headquartered in Korneuburg, Austria, develops innovative biotech solutions. The Marinosolv technology enhances the solubility and bioavailability of compounds, targeting immune disorders. The company's stocks are listed on the Vienna Stock Exchange.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Marinomed Biotech AG news